Skip to content

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080224696
Enrollment
472
Registered
2019-05-22
Start date
2019-06-03
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

investigational material(s) Generic name etc : LY3298176 INN of investigational material : - Therapeutic category code : 249 Other hormone preparations (including antihormone preparations) Dosage and

Sponsors

Eli Lilly Japan K.K.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
confirmatory efficacy

Secondary

MeasureTime frame
efficacy confirmatory safety exploratory pharmacokinetics

Countries

Asia except Japan, Japan, North America, South America

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026